John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$510M |
| 2 |
Broadcom
AVGO
|
+$318M |
| 3 |
Marvell Technology
MRVL
|
+$290M |
| 4 |
Salesforce
CRM
|
+$263M |
| 5 |
Advanced Micro Devices
AMD
|
+$250M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$255M |
| 2 |
Progressive
PGR
|
+$244M |
| 3 |
Visa
V
|
+$238M |
| 4 |
Lam Research
LRCX
|
+$201M |
| 5 |
Elevance Health
ELV
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.88% |
| 2 | Healthcare | 13.28% |
| 3 | Financials | 10.32% |
| 4 | Industrials | 9.79% |
| 5 | Consumer Discretionary | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Zevia
ZVIA
$101M
| $97.9K | ﹤0.01% |
+45,307
| New | +$148K |
|
2902
Compass Therapeutics
CMPX
$432M
| $97.4K | ﹤0.01% |
51,239
-93,999
| -65% | -$250K |
|
2903
Cumberland Pharmaceuticals
CPIX
$117M
| $96.3K | ﹤0.01% |
22,755
-14,894
| -40% | -$61.8K |
|
|
OPI
2904
DELISTED
Office Properties Income Trust
OPI
| $92K | ﹤0.01% |
201,864
-106,036
| -34% | -$90.5K |
|
2905
Aligos Therapeutics
ALGS
$43.3M
| $91.2K | ﹤0.01% |
+11,050
| New | +$242K |
|
2906
Kosmos Energy
KOS
$1.7B
| $90.9K | ﹤0.01% |
+39,886
| New | +$118K |
|
|
NINE
2907
DELISTED
Nine Energy Service
NINE
| $90.4K | ﹤0.01% |
79,998
+32,304
| +68% | +$39.7K |
|
2908
Virgin Galactic
SPCE
$455M
| $89.8K | ﹤0.01% |
29,625
-376,229
| -93% | -$1.65M |
|
2909
Palladyne AI
PDYN
$285M
| $89.5K | ﹤0.01% |
15,214
+79
| +0.5% | +$642 |
|
2910
Codexis
CDXS
$182M
| $88.5K | ﹤0.01% |
32,908
-230,310
| -87% | -$893K |
|
|
NFGC
2911
New Found Gold
NFGC
$730M
| $88.3K | ﹤0.01% |
73,617
-13,168
| -15% | -$22.7K |
|
2912
Vor Biopharma
VOR
$1.34B
| $88.2K | ﹤0.01% |
6,150
-2,003
| -25% | -$48.1K |
|
|
HBI
2913
DELISTED
Hanesbrands
HBI
| $88K | ﹤0.01% |
15,257
-33,875
| -69% | -$237K |
|
2914
Nexa Resources
NEXA
$2.02B
| $87.7K | ﹤0.01% |
+14,144
| New | +$83.2K |
|
2915
Companhia Siderúrgica Nacional
SID
$1.37B
| $87.7K | ﹤0.01% |
52,501
-155,116
| -75% | -$238K |
|
|
SHCO
2916
DELISTED
Soho House & Co
SHCO
| $87.1K | ﹤0.01% |
+14,098
| New | +$102K |
|
2917
Genelux
GNLX
$123M
| $84.5K | ﹤0.01% |
31,292
-9,885
| -24% | -$37.1K |
|
2918
Smart Sand
SND
$198M
| $84K | ﹤0.01% |
32,422
-2,099
| -6% | -$4.93K |
|
|
ORGN
2919
DELISTED
Origin Materials
ORGN
| $82.3K | ﹤0.01% |
4,134
-6,461
| -61% | -$178K |
|
2920
Cineverse
CNVS
$60.4M
| $81.4K | ﹤0.01% |
25,764
-10,143
| -28% | -$38K |
|
2921
Shattuck Labs
STTK
$793M
| $81K | ﹤0.01% |
85,238
-45,441
| -35% | -$56K |
|
2922
American Well
AMWL
$203M
| $80.4K | ﹤0.01% |
10,205
-9,011
| -47% | -$85.8K |
|
|
INZY
2923
DELISTED
Inozyme Pharma
INZY
| $80.2K | ﹤0.01% |
88,093
+56,169
| +176% | +$77.9K |
|
2924
Metagenomi Therapeutics
MGX
$45.7M
| $79.4K | ﹤0.01% |
58,348
+31,877
| +120% | +$76K |
|
2925
Destination XL Group
DXLG
$35.2M
| $78.8K | ﹤0.01% |
53,986
-23,806
| -31% | -$55.7K |
|
Similar funds
John Overdeck's Q1 2025 Portfolio in Review
As of Q1 2025, John Overdeck held 3,617 positions worth $46.8B, up 2% from $45.9B the previous quarter. Its ten largest holdings account for 8.1% of the portfolio.
John Overdeck deployed $2.08B of net new capital in Q1 2025, opening 458 new positions and adding to 1,225 existing holdings. Its largest new stake was Advanced Micro Devices: 2,246,952 shares worth $231M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $255M trimmed.
- John Overdeck's largest Q1 2025 buy was Advanced Micro Devices: 2,246,952 shares worth $231M.
- John Overdeck added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $510M increase.
- John Overdeck's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $255M.
- John Overdeck fully exited Coinbase in Q1 2025, selling an estimated $45M.
- John Overdeck's ten largest holdings make up 8.1% of its $46.8B portfolio in Q1 2025.
- John Overdeck opened 458 new positions and closed 452 in Q1 2025.
- John Overdeck's portfolio value rose 2% quarter-over-quarter to $46.8B.
Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.